AI-designed universal coronavirus vaccine completed Phase 1 trial with 100% safety and no serious reactions Vaccine targets conserved core virus features, providing immunity against multiple coronavirus strains Trial used needle-free DNA delivery via microfluidic jet, reducing pain and medical waste risks